Clinical Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kuniyasu, H.
Right arrow Articles by Fidler, I. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kuniyasu, H.
Right arrow Articles by Fidler, I. J.
Clinical Cancer Research Vol. 5, 25-33, January 1999
© 1999 American Association for Cancer Research

Advances in Brief

Relative Expression of E-Cadherin and Type IV Collagenase Genes Predicts Disease Outcome in Patients with Resectable Pancreatic Carcinoma1

Hiroki Kuniyasu, Lee M. Ellis, Douglas B. Evans, James L. Abbruzzese, Claudia J. Fenoglio, Corazon D. Bucana, Karen R. Cleary, Eiichi Tahara and Isaiah J. Fidler2

Departments of Cancer Biology [H. K., L. M. E., C. D. B., I. J. F.], Surgical Oncology [L. M. E., D. B. E., C. J. F.], Gastrointestinal Medical Oncology [J. L. A.], and Pathology [K. R. C.], The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, and First Department of Pathology, Hiroshima University School of Medicine, Hiroshima 734, Japan [E. T.]


   ABSTRACT
Top
 ABSTRACT
Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 
We examined the expression level of several genes that regulate distinct steps of metastasis in formalin-fixed, paraffin-embedded, archival specimens of primary human pancreatic carcinomas from patients undergoing curative surgery. The expression of epidermal growth factor receptor, E-cadherin, type IV collagenase [matrix metalloproteinase (MMP) 2 and MMP-9), basic fibroblast growth factor, vascular endothelial growth factor/vascular permeability factor, and interleukin 8 was examined by a colorimetric in situ mRNA hybridization technique. Down-regulation of E-cadherin and up-regulation of type IV collagenase (MMP-9 and MMP-2) at the periphery of the neoplasms (P = 0.0167, 0.0102, and 0.0349, respectively) had significant prognostic value. The ratio of type IV collagenase expression (mean of the expression of MMP-2 and MMP-9) to E-cadherin expression (MMP:E-cadherin ratio) at the periphery of the tumors was significantly higher in patients with recurrent disease (4.7 ± 2.1) than in patients who were disease free (2.3 ± 1.7; P = 0.0008). Death from pancreatic cancer was significantly associated with a high MMP:E-cadherin ratio (>3.0) by overall survival analysis (P < 0.0002), whereas a low MMP:E-cadherin ratio (<3.0) was found in seven of eight patients alive 28–64 months after surgery. Multivariate analysis of overall survival showed that the MMP:E-cadherin ratio was a significant independent prognostic factor, whereas stage, nodal metastasis, and histological type were not. These data show that multiparametric analysis for several metastasis-related genes may allow physicians to assess the metastatic potential and hence predict the clinical outcome of individual patients with resectable pancreatic carcinoma.


   Introduction
Top
 ABSTRACT
 Introduction
Materials and Methods
 Results
 Discussion
 REFERENCES
 
Pancreatic cancer is the fifth leading cause of adult cancer mortality (1 , 2) . Patients undergoing surgical resection for pancreatic adenocarcinoma at its most common site, the pancreatic head (3) , have a 5-year survival rate of only 13–25% (4, 5, 6) and a median survival of only 12–24 months (4, 5, 6, 7) . The disease recurs locally in 80% of patients (8) , liver metastasis appears in 50–70% of patients (8 , 9) , and abdominal carcinomatosis appears in 50% of patients (8 , 9) . At the University of Texas M. D. Anderson Cancer Center, the current management of patients with pancreatic cancer involves selective laparotomy based on accurate radiographic imaging techniques and reliable, minimally invasive techniques for biliary decompression, a standardized surgical procedure and preoperative patient management, and multimodality therapy in all patients with localized, potentially resectable disease (10 , 11) . This approach has maximized the overall survival of patients with localized pancreatic carcinoma and allows patients with advanced disease to avoid the morbidity of surgery (12) .

The prognosis and choice of therapy for any human neoplasm, especially an aggressive disease such as pancreatic carcinoma, are based on the stage of the disease and its metastatic potential. Traditionally, these parameters have been determined by microscopic examination of tissue sections from the primary neoplasm. Unfortunately, routine histopathological examination of the primary tumor cannot always identify the patients at highest risk for recurrence (13) . Recently, however, advances in molecular biology and in our understanding of the pathogenesis of cancer metastasis have provided new tools with which to predict the metastatic potential of human cancers, including pancreatic carcinoma.

Molecular analysis of human pancreatic adenocarcinomas has revealed several abnormalities of oncogenes or tumor suppressor genes, including the K-ras gene (14, 15, 16) , p53 gene (16, 17, 18, 19) , pl6 gene (20) , and DPC4 gene (21) . These studies have improved our understanding of pancreatic tumorigenesis, but not necessarily that of the metastatic potential of an individual tumor.

The metastatic potential of solid tumors has been shown to correlate directly with the expression level of several independent genes that regulate: growth (EGF-R),3 angiogenesis (bFGF, VEGF/vascular permeability factor, and IL-8), invasion (type IV collagenase genes), and multidrug resistance (mdr-1; Refs. 22, 23, 24, 25, 26, 27 ). In several reports, the expression of E-cadherin, which is directly related to cell-to-cell cohesion, is inversely correlated with tumor progression and metastasis (22) . Most of these correlative studies suggest that the expression of a given gene is necessary but not sufficient to account for the multistep process of metastasis (23) . Because each of the discrete steps in the pathogenesis of metastasis is regulated by one or several independent genes, the identification of cells with metastatic potential in heterogeneous primary human tumors requires a multiparametric/multivariate analysis of gene expression (23) .

We have previously examined the expression of these metastasis-related genes in colorectal carcinomas (22 , 24 , 25) , gastric carcinomas (26) , and prostate carcinomas (27) . One factor consistently down-regulated in metastatic tumors is E-cadherin, a transmembrane glycoprotein responsible for homotypic binding and morphogenesis of epithelial tissues (28 , 29) . In epithelial neoplasms, reduced or absent expression of E-cadherin is associated with a decrease in cellular and tissue differentiation and a higher metastatic potential (30, 31, 32, 33, 34, 35, 36, 37) . Furthermore, transfection of E-cadherin cDNA into carcinoma cells inhibits motility and invasiveness (38 , 39) . Another factor altered in metastatic tumors is type IV collagenase, a member of the matrix-degrading proteinase family, the MMPs (40) . Type IV collagen is a major component of blood vessel basement membrane, and its degradation is essential in tumor cell invasion of the vasculature. Type IV collagenase consists of two forms of MMPs: (a) a Mr 92,000 type IV collagenase (MMP-9, gelatinase B); and (b) a Mr 72,000 type IV collagenase (MMP-2, gelatinase A), both of which demonstrate a similar catalytic profile (41 , 42) . The expression of both types of MMPs directly correlates with invasion and metastasis in human carcinomas (43 , 44) . Because down-regulation of E-cadherin coupled with up-regulation of collagenase type IV favors invasion and metastasis, the ratio of collagenase type IV expression to E-cadherin expression was demonstrated to be associated with metastasis and recurrence of colon carcinoma (22) and distant lymph node metastasis in gastric carcinoma (26) .

In this study, we extended this research to adenocarcinoma of the pancreas. We used our recently developed rapid calorimetric ISH technique to detect mRNA in frozen tissues (45) and formalin-fixed, paraffin-embedded tissues (46) . We used ISH to study the expression level of several genes that regulate different steps in the metastatic cascade and conclude that the expression level of metastasis-related genes correlates with the clinical outcome of resectable human pancreatic carcinoma.


   Materials and Methods
Top
 ABSTRACT
 Introduction
 Materials and Methods
Results
 Discussion
 REFERENCES
 
Surgical Specimens.
Twenty-two formalin-fixed, paraffin-embedded, archival surgical specimens of primary pancreatic adenocarcinomas from patients treated at the University of Texas M. D. Anderson Cancer Center were chosen at random. Twenty-one patients underwent pancreaticoduodenectomy (Whipple operation), and one patient underwent distal pancreatectomy. Sixteen patients were postoperatively treated with adjuvant chemotherapy and/or radiation therapy. The clinicopathological data of these patients are detailed in Table 1Citation . Patients were followed on a prospective basis, and the information collected was entered in a database. None of the patients received preoperative chemotherapy. The specimens were classified by stages according to the American Joint Committee on Cancer (47) and by histological types according to Solcia et al. (9) . Only specimens with intact mRNA as determined by positive reaction with the poly(dT)20 probe (25 , 45) were evaluated for expression of the metastasis-related genes.


View this table:
[in this window]
[in a new window]

  		Table 1 Clinicopathological data

 
Oligonucleotide Probes.
Specific antisense oligonucleotide DNA probes were designed complementary to the mRNA transcripts of seven metastasis-related genes (Table 2)Citation , based on published reports of the cDNA sequences (40 , 46 , 48, 49, 50, 51, 52, 53, 54, 55) . The specificity of the oligonucleotide sequences was initially determined by a GenBank/European Molecular Biology Laboratory database search using the Genetics Computer Group sequence analysis program (Genetics Computer Group, Madison, WI) based on the FastA algorithm (56) that showed 100% homology with the target gene and minimal homology with nonspecific mammalian gene sequences. The specificity of each sequence was also confirmed by Northern blot analysis. A poly(dT)20 oligonucleotide was used to verify the integrity of mRNA in each sample. All DNA probes were synthesized with six biotin molecules (hyperbiotinylated) at the 3' end via direct coupling using standard phosphormidine chemistry (Research Genetics, Huntsville, AL; Refs. 57 and 58 ). The lyophilized probes were reconstituted to a 1 µg/µl stock solution in 10 mmol/liter Tris-HCl (pH 7.6) and 1 mmol/liter EDTA. The stock solution was diluted with Probe Diluent (Research Genetics) immediately before use. The working dilutions of each probe are shown in Table 2Citation .


View this table:
[in this window]
[in a new window]

  		Table 2 Sequence of oligonucleotide probes

 
ISH.
ISH was performed as described previously (45 , 46) with a minor modification. ISH was carried out using the Microprobe manual staining system (Fisher Scientific, Pittsburgh, PA; Ref. 59 ). Tissue sections (4 µm) of formalin-fixed, paraffin-embedded specimens were mounted on Silane-coated ProbeOn slides (Fisher Scientific). The slides were placed in the Microprobe slide holder, dewaxed, and dehydrated with Autodewaxer and Autoalcohol (Research Genetics), followed by enzymatic digestion with pepsin (57) . Hybridization of the probe was carried out for 60 min at 45°C, and the samples were then washed three times with 2x SSC for 2 min at 45°C. The samples were incubated for 30 min in alkaline phosphatase-labeled avidin at 45°C, briefly rinsed in 50 mM Tris buffer (pH 7.6), rinsed for 1 min with alkaline phosphatase enhancer (Biomeda Corp., Foster City, CA), and incubated for 30 min with the chromogen substrate FastRed (Research Genetics) at 45°C. A positive reaction in this assay stained red. Control for endogenous alkaline phosphatase included treatment of the samples in the absence of the biotinylated probe and use of chromogen in the absence of any oligonucleotide probes. To check the specificity of the hybridization signal, the following controls were used: (a) RNase pretreatment of tissue sections; (b) a biotin-labeled sense probe; and (c) a competition assay with unlabeled antisense probe. A markedly decreased or absent signal was obtained after all of these treatments.

Image Analysis to Quantify Intensity of Color Reaction.
Stained sections were examined in a Zeiss photomicroscope (Carl Zeiss, Inc., Thomwood, NY) equipped with a three-chip charged-coupled device color camera (model DXC-960 MD; Sony Corp., Tokyo, Japan). The images were analyzed using the Optimas image analysis software (version 5.2; Bothell, WA). The slides were prescreened by one of the investigators to determine the range in staining intensity of the slides to be analyzed. Images covering the range of staining intensities were captured electronically, a color bar (montage) was created, and a threshold value was set in the red, green, and blue mode of the color camera. All subsequent images were quantified based on this threshold. The integrated absorbance of the selected fields was determined based on its equivalence to the mean log inverse gray scale value multiplied by the area of the field. The samples were not counterstained, so the absorbance was due solely to the product of the ISH reaction. For each section, we determined the absorbance in several 2 x 2-mm zones located at the center and periphery of the tumors or at the foci of perineural invasion. Three to five different fields in each 2 x 2-mm zone were quantified to derive an average value. The intensity of staining was standardized to that of the integrated absorbance of poly(dT)20 and determined by comparison with the integrated absorbance of nonpathological pancreatic duct epithelium, which was set at 100.

Statistical Analysis.
The patients were stratified according to stage (47) , histological type (9) , invasion status at the periphery and center of the tumor, perineural invasion, amount of fibrous stroma, and hyperplastic changes in the pancreatic duct mucosa adjacent to the tumor. The level of gene expression among the groups was compared by the Mann-Whitney U test (60) . Survival analysis was computed by the Kaplan-Meier method (61) and compared by log-rank test (62) . Univariate and multivariate analyses of survival were conducted using the Cox proportional hazards model and log normal model (60 , 63) . Statistical significance was defined as a two-sided P < 0.05 (60) .


   Results
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
Discussion
 REFERENCES
 
Intratumoral Heterogeneity for the Expression of E-Cadherin and Type IV Collagenase Genes in Pancreatic Carcinomas.
The integrity of mRNA in each sample was first verified by using a poly(dT)20 probe (25 , 45) . All samples had an intense histochemical reaction, indicating that the mRNA was well preserved. Previous reports analyzing the expression of metastasis-related genes in human colon carcinomas (22) and human gastric carcinomas (26) concluded that the expression level of E-cadherin and collagenase type IV varied between the center and periphery of the lesions. Moreover, the ratio between E-cadherin and collagenase type IV expression predicted disease outcome. For this reason, we examined the expression level of E-cadherin, MMP-9, and MMP-2 at the periphery (invasive edge), the center of the tumor, and in the adjacent nonpathological duct epithelium. The expression level of these metastasis-related genes differed at the periphery and center of the tumors (Table 3Citation ; Fig. 1Citation ). In 20 of 22 cases (91%), the expression of E-cadherin was significantly lower at the periphery than in the center (P = 0.0167). In contrast, the expression level of type IV collagenase was higher at the periphery as compared with the center of the tumors. In fact, up-regulation of MMP-9 and MMP-2 at the periphery was found in 19 of 22 (86%) and 20 of 22 (91%) cases, respectively. The mean expression of MMP-9 and MMP-2 was significantly higher at the periphery than at the center (P = 0.0102 and 0.0347, respectively). Because down-regulation of E-cadherin and up-regulation of type IV collagenases were found at the periphery of the tumors, the MMP:E-cadherin expression level ratio was highest at the periphery of all tumors, differing significantly from that found in the center (P = 0.0039; Mann-Whitney U test). These data agree with the previous reports (22 , 26) suggesting that analysis of the metastatic potential of human neoplasms should focus on the tumor’s peripheral zone. All further analyses therefore examined the expression of metastasis-related genes at the periphery of the tumors (Table 4)Citation .


View this table:
[in this window]
[in a new window]

  		Table 3 Intratumoral heterogeneity of the expression of E-cadherin, MMP-9, and MMP-2

 


View larger version (133K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 1. ISH analysis of E-cadherin and MMP-2 mRNA at the center and periphery of a stage III pancreatic cancer and tumor-free tissue (case 10). H&E staining shows that the tumor is moderately differentiated (A1, B1, and C1). Hybridization with hyperbiotinylated poly(dT)20 probe confirmed the integrity and lack of mRNA degradation. A positive reaction in this assay stains red. The expression intensity for E-cadherin and MMP-2 in tumor-free tissue (C2 and C3) was assigned a value of 100. In the center of the tumor (A2 and A3), the expression intensity values for E-cadherin and MMP-2 were 82 and 198 (MMP:E-cadherin ratio, 2.5), whereas at the periphery (B2 and B3), the intensity values for E-cadherin and MMP-2 were 54 and 237, respectively (MMP:E-cadherin ratio, 3.9).

 

View this table:
[in this window]
[in a new window]

  		Table 4 Relationship between expression of metastasis-related genes and clinicopathological features

 
Foci of perineural invasion, a characteristic of human pancreatic adenocarcinoma (9 , 64) , were found and examined in nine tumors. Although most of the foci of perineural invasion were found at the periphery of the tumor, the expression of E-cadherin and type IV collagenase was similar to that found in the center of the tumor (Table 3)Citation .

Expression of Metastasis-related Genes Predicts Disease Outcome.
To determine the prognostic relevance of the ISH analysis (especially the MMP:E-cadherin expression ratio at the periphery of the lesions), we compared the ISH findings with the clinicopathological data (Table 4)Citation . The expression of EGF-R, bFGF, VEGF, or IL-8 did not correlate with the stage of disease, degree of differentiation, histological type, fibrous stroma and hyperplasia of the pancreatic duct (Tables 1Citation and 4)Citation , or clinical status (Table 4)Citation . In contrast, the MMP:E-cadherin ratio correlated with disease-free survival. In 12 dead patients with a mean survival time of 25 ± 21 months, the mean ratio was 4.7 ± 2.1, whereas in 10 living patients with a mean survival time of 42 ± 17 months, the mean ratio was 2.3 ± 1.7. The differences in MMP:E-cadherin ratios were highly significant (P = 0.0008, Mann-Whitney U test), as were the differences in overall disease-free survival time (P = 0.0062, Fisher’s exact test) and mean survival time (P = 0.0029, Mann-Whitney U test). Moreover, 11 of 14 patients (79%) with high MMP:E-cadherin ratios (>3.0) died from recurrent disease, whereas 7 of 8 patients (88%) with low MMP:E-cadherin ratios (<3.0) were alive 28–64 months after surgery without disease.

The MMP:E-cadherin expression ratio at the periphery of the resected pancreatic cancers also correlated with the overall survival analyzed by the Kaplan-Meier method. These data, shown in Fig. 2Citation , differed significantly between the two groups of patients (P < 0.001, log-rank test). Patient survival also correlated with the expression of E-cadherin and MMP-9 (P = 0.0008 and 0.0249, respectively, Mann-Whitney U test; Table 4Citation ). Neither tumor stage (I, II, or III) nor histological classification (state of differentiation) correlated with the expression of metastasis-related genes, the ratio of MMP:E-cadherin, or overall disease-free survival.



View larger version (17K):
[in this window]
[in a new window]
[Download PPT slide]
  		Fig. 2. Correlation of survival with the MMP:E-cadherin expression ratio in resected pancreatic cancer. Overall survival of patients with resected pancreatic carcinomas stratified by the expression ratio between MMP and E-cadherin genes in the surgical specimens was analyzed by the Kaplan-Meier method. The overall survival differed significantly between the group with tumors exhibiting a MMP:E-cadherin ratio of <3.0 and >3.0 (P = 0.001, log-rank test).

 
The prognostic significance of the clinicopathological parameters (Tables 1Citation and 4)Citation and the expression of metastasis-related genes were analyzed by univariate and multivariate analysis using the Cox proportional hazards model and the log normal model. The data summarized in Table 5Citation demonstrate that the most significant independent prognostic parameter for survival was the MMP:E-cadherin ratio, followed by the expression level of E-cadherin.


View this table:
[in this window]
[in a new window]

  		Table 5 Univariate analysis of overall survival rates

 

   Discussion
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
REFERENCES
 
In archival surgical specimens of primary human pancreatic carcinomas, we examined the expression level of several genes that regulate steps of pancreatic cancer metastasis. The present results show that the expression of metastasis-related genes, especially the ratio between the expression of MMP-2/MMP-9 and E-cadherin, closely correlated with disease recurrence and patient survival. In contrast, nodal metastasis, advanced pathological stage, and stage of differentiation were not predictive of decreased patient survival, results that may be due to the relatively small sample size (4 , 65, 66, 67) . We have reported previously that the metastatic potential of human colon cancers (22) and human gastric cancers (26) can be identified by a multiparametric analysis for the expression of genes that encode for EGF-R (growth), bFGF and IL-8 (angiogenesis), E-cadherin (cohesion), and MMP-2 and MMP-9 (invasion). Specifically, the down-regulation of the cell-to-cell cohesion molecule E-cadherin (28 , 29) concurrent with the up-regulation of the proteolytic enzymes MMP-2 and MMP-9 accurately predicted metastasis and disease recurrence (22 , 26) . Similar findings were also reported for human prostate cancer cells with low and high metastatic potential (27) .

Like other neoplasms, human pancreatic adenocarcinomas consist of multiple cell types, including tumor cells and host fibroblasts, epithelial, endothelial, and infiltrating cells (68) . Because metastases can be produced by a small subpopulation of tumor cells (<1.0% of the tumor; Refs. 68, 69, 70) , detecting the expression of metastasis-related genes in the minority of tumor cells requires a sensitive technique. We chose ISH because it identifies the cellular source of the mRNA as well as intratumoral heterogeneity in expression, whereas Northern blot analysis represents only the average levels of mRNA of all of the cells in a sample (25) . As was the case for human colon carcinomas (22) and human gastric carcinomas (26) , the expression of E-cadherin and collagenase type IV differed between the center and periphery of the pancreatic cancers.

E-Cadherin is a cell surface glycoprotein involved in calcium-dependent homotypic cell-to-cell adhesion (71) . It is localized at the epithelial junction complex and is responsible for the organization, maintenance, and morphogenesis of epithelial tissues (29 , 72) . Reduced levels of E-cadherin are associated with a decrease in cellular/tissue differentiation and increased histological grade in different epithelial neoplasms (30, 31, 32, 33, 34 , 73, 74, 75) . Transfection of E-cadherin-encoding cDNA into invasive cancer cells has been shown to inhibit their invasiveness (38) .

Once cells detach from the primary tumor, they must invade the host stroma if they are to metastasize. Degradation of blood vessel basement components, especially type IV collagen, is one of the necessary steps in metastasis. The levels of Mr 72,000 and Mr 92,000 type IV collagenase in human and rodent neoplasms directly correlate with invasion and metastasis (43 , 44 , 76, 77, 78, 79) , and specific inhibitors of MMPs have been shown to inhibit tumor cell invasion (78, 79, 80, 81) . Thus, a decrease in the expression of E-cadherin and an increase in collagenase type IV activity should enhance tumor cell invasion and metastasis. Regardless of the pathological stage of the primary tumor, a MMP:E-cadherin ratio of >3.0 directly correlated with disease recurrence and inversely correlated with survival. Our data conclude that this MMP:E-cadherin expression ratio is at the periphery of patients undergoing curative pancreatectomy.

Perineural invasion is characteristic of human pancreatic cancer (4 , 9 , 64 , 82) . The MMP:E-cadherin ratio in cancer cells in the foci of perineural invasion was <3.0. Thus, these cells did not share the phenotype of cancer cells at the periphery of the lesions. Perineural invasion may therefore relate to the affinity of tumor cells to migrate to peripheral neural tissue expressing neural cell adhesion molecule (83) .

In summary, we used the ISH technique described here to examine the concurrent expression of metastasis-related genes in formalin-fixed, paraffin-embedded specimens of resected human pancreatic adenocarcinomas from patients undergoing curative surgery. Using quantification of gene expression by colorimetric scanning and standardization to nonpathological duct mucosa cells allowed an examination of individual specimens. We conclude that the ratio between the expression of MMP-2/MMP-9 and E-cadherin at the periphery of the neoplasms would accurately predict outcome. These data show that multiparametric analysis for several metastasis-related genes may allow physicians to assess the metastatic potential and hence predict the clinical outcome of individual patients with resectable pancreatic carcinoma.


   ACKNOWLEDGMENTS
 
We thank Walter Pagel for critical review and Lola López for expert assistance in the preparation of the manuscript.


   FOOTNOTES
 
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

1 Supported in part by Cancer Center Support Core Grant CA 16672 and Grant R35-CA 42107 from the National Cancer Institute, NIH. Back

2 To whom requests for reprints should be addressed, at Department of Cancer Biology, Box 173, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: (713) 792-8577; Fax: (713) 792-8747. Back

3 The abbreviations used are: EGF-R, epidermal growth factor receptor; bFGF, basic fibroblast growth factor; IL, interleukin; MMP, matrix metalloproteinase; ISH, in situ hybridization; VEGF, vascular endothelial growth factor. Back

Received 7/21/98; revised 10/ 8/98; accepted 10/26/98.


   REFERENCES
Top
 ABSTRACT
 Introduction
 Materials and Methods
 Results
 Discussion
 REFERENCES
 

  1. Boring C. C., Squires T. S., Tong T., Montogomery S. Cancer Statistics. CA Cancer J. Clin., 44: 7-26, 1994.[Medline]
  2. Wingo A. P., Tong T., Bolden S., Squire T. S., Taong T. Cancer statistics, 1995. CA Cancer J. Clin., 5: 3-30, 1995.
  3. Allen-Mersh T. G. Significance of the site of origin of pancreatic exocrine adenocarcinoma. J. Clin. Pathol., 35: 544-546, 1982.[Abstract/Free Full Text]
  4. Nitecki S. S., Sarr M. G., Colby T. V., van Heerden J. A. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving?. Ann. Surg., 221: 59-66, 1995.[Medline]
  5. Evans D. B., Abbruzzese J. L., Rich T. A. Cancer of the pancreas 5th ed. deVita V. T., Jr. Hellman S. Rosenberg S. A. eds. . Cancer: Principles and Practice of Oncology, : 1054-1087, Lippincott-Raven Press Philadelphia 1997.
  6. Cameron J. L., Crist D. W., Sitzmann J. V., Hruban R. H., Boinott J. K., Seider A. J., Coleman J. Factors influencing survival after pancreaticoduodenectomy for pancreatic cancer. Am. J. Surg., 161: 120-125, 1991.[Medline]
  7. Connolly M. M., Dawson P. J., Michelassi F., Moosa A. R., Lowenstein F. Survival in 1001 patients with carcinoma of the pancreas. Ann. Surg., 206: 366-373, 1987.[Medline]
  8. Kayahara M., Nagakawa T., Ueno K., Ohta T., Takeda T., Miyazaki I. An evaluation of radical resection for pancreatic cancer based on the mode of recurrence as determined by autopsy and diagnostic imaging. Cancer (Phila.), 72: 2118-2123, 1993.[Medline]
  9. Solcia E., Capella C., Klöppel G. Tumors of the pancreas 3rd ed. Rosai J. Sobin L. H. eds. . Atlas of Tumor Pathology, : 31-144, Armed Forces Institute of Pathology Washington, DC 1997.
  10. Miller A. R., Robinson E. K., Lee J. E., Pisters P. W. T., Chiao P. J., Lenzi R. L., Abbruzzese J. L., Evans D. B. Neoadjuvant chemoradiation for adenocarcinoma of the pancreas. Surg. Oncol. Clin. N. Am., 7: 183-197, 1998.[Medline]
  11. Spitz F. R., Abbruzzese J. L., Lee J. E., Pisters P. W., Lowy A. M., Fenoglio C. J., Cleary K. R., Janjan N. A., Goswitz M. S., Rich T. A., Evans D. B. Preoperative and postoperative chemoradiation strategies in patients treated with pancreaticoduodenectomy for adenocarcinoma of the pancreas. J. Clin. Oncol., 15: 928-937, 1997.[Abstract/Free Full Text]
  12. Staley C. A., Lee J. E., Cleary K. R., Abbruzzese J. L., Fenoglio C. J., Rich T. A., Evans D. B. Preoperative chemoprevention, pancreaticoduodenectomy, and intraoperative radiation therapy for adenocarcinoma of the pancreatic head. Am. J. Surg., 171: 118-124, 1996.[Medline]
  13. Yasui W., Yokozaki H., Tahara E. Molecular diagnosis of gastrointestinal cancer Tahara E. eds. . Molecular Pathology of Gastroenterological Cancer, : 187-207, Springer-Verlag Tokyo 1997.
  14. Almoguerra C., Shibata D., Forrester K., Martin J., Arnheim N., Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell, 53: 549-554, 1988.[Medline]
  15. Hruban R. H., van Mansfeld A. D. M., Offerhaus G. J., van Weering D. H. J., Allison D. C., Goodman S. N., Kensler T. W., Bose K. K., Cameron J. L., Bos J. L. K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am. J. Pathol., 143: 545-554, 1993.[Abstract]
  16. Pellegata N. S., Sessa F., Renault B., Bonato M., Leone B. E., Solcia E., Ranzani G. N. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res., 54: 1556-1560, 1994.[Abstract/Free Full Text]
  17. Hahn S. A., Kern S. E. Molecular genetics of exocrine pancreatic neoplasms. Surg. Clin. N. Am., 75: 875-879, 1995.
  18. Lee E. Y., Cibull M. L., O’Daniel-Pierce E., Strodel W. E., Jennings C. D. Expression of p53 protein in pancreatic adenocarcinoma. Int. J. Pancreatol., 17: 237-242, 1995.[Medline]
  19. Sinicrope F. A., Evans D. B., Leach S. D., Cleary K. R., Fenoglio C. J., Lee J. J., Abbruzzese J. L. Bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome. Clin. Cancer Res., 2: 2015-2022, 1996.[Abstract]
  20. Cadas C., Hanh S. A., da Costa L. T., Redson M. S., Schutte M., Seymour A. B., Weinstein C. L., Hruban R. H., Yeo C., Kern S. E. Frequent somatic mutations and homozygous deletions of the p16 (MST1) gene in pancreatic adenocarcinomas. Nat. Genet., 8: 27-32, 1994.[Medline]
  21. Hahn S. A., Schutte M., Hoque A. T., Moskaluk C. A., da Costa L. T., Rozenblum E., Weinstein C. L., Fischer A., Yeo C. J., Hruban R. H., Kern S. E. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science (Washington DC), 271: 350-353, 1996.[Abstract]
  22. Kitadai Y., Ellis L. M., Tucker S. L., Greene G. F., Bucana C. D., Cleary K. R., Takahashi Y., Tahara E., Fidler I. J. Multiparametric in situ mRNA hybridization analysis to predict disease recurrence in patients with colon carcinoma. Am. J. Pathol., 149: 1541-1551, 1996.[Abstract]
  23. Fidler I. J., Radinsky R. Genetic control of cancer metastasis. J. Natl. Cancer Inst., 82: 166-168, 1990.[Free Full Text]
  24. Kitadai Y., Bucana C. D., Ellis L. M., Anzai H., Tahara E., Fidler I. J. In situ hybridization technique for analysis of metastasis-related genes in human colon carcinoma cells. Am. J. Pathol., 147: 1238-1247, 1995.[Abstract]
  25. Kitadai Y., Ellis L. M., Takahashi Y., Bucana C. D., Anzai H., Tahara E., Fidler I. J. Multiparametric in situ messenger RNA hybridization analysis to detect metastasis-related genes in surgical specimens of human colon carcinomas. Clin. Cancer Res., 1: 1095-1102, 1995.[Abstract]
  26. Anzai H., Kitadai Y., Bucana C. D., Sanchez R., Omoto R., Fidler I. J. Intratumoral heterogeneity and inverse correlation between expression of E-cadherin and collagenase type IV in human gastric carcinomas. Differentiation, 60: 119-127, 1996.[Medline]
  27. Greene G. F., Kitadai Y., Pettaway C. A., von Eschenbach A. C., Fidler I. J. In situ mRNA hybridization technique for analysis of metastasis-related genes in human prostate carcinoma cells. Am. J. Pathol., 150: 1571-1582, 1996.[Abstract]
  28. Takeichi M. The cadherins: cell-cell adhesion molecules controlling animal morphogenesis. Development (Camb.), 102: 639-655, 1988.[Abstract/Free Full Text]
  29. Takeichi M. Cadherin cell adhesion receptor as a morphogenic regulator. Science (Washington DC), 251: 1451-1455, 1991.[Abstract/Free Full Text]
  30. Kadowaki T., Shiozaki H., Inoue M., Tamura S., Oka H., Doki Y., Iihara K., Matsui S., Iwazawa T., Nagafuchi A., Tsukita S., Mori T. E-Cadherin and {alpha}-catenin expression in human esophageal cancer. Cancer Res., 54: 291-296, 1994.[Abstract/Free Full Text]
  31. Mayer B., Johnson J. P., Leitl F., Jauch K. W., Heiss M. M., Schildberg F. W., Birchmeier W., Funke I. E-Cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res., 53: 1690-1695, 1993.[Abstract/Free Full Text]
  32. Yasui W., Kuniyasu H., Akama Y., Kitahara K., Nagafuchi A., Ishihara S., Tsukita S., Tahara E. Expression of E-cadherin, {alpha}- and ß-catenins in human gastric carcinomas: correlation with histology and tumor progression. Oncol. Rep., 2: 111-117, 1995.
  33. Dorudi S., Sheffield J. P., Poulsom R., Northover J. M., Hart I. R. E-Cadherin expression in colorectal cancer: an immunocytochemical and in situ hybridization study. Am. J. Pathol., 142: 981-986, 1993.[Abstract]
  34. Brabant G., Hoang-Yu C., Cetin Y., Dralle H., Scheumann G., Moelne J., Hansson G., Jansson S., Ericson L. E., Nisson M. E-Cadherin: a differentiation marker in thyroid malignancies. Cancer Res., 53: 4987-4993, 1993.[Abstract/Free Full Text]
  35. Mattijssen V., Peters H. M., Schalkwijk L., Manni J. J., Van’t Hof Grootenboer B., de Mulder P. H., Ruiter D. J. E-Cadherin expression in head and neck squamous-cell carcinoma is associated with clinical outcome. Int. J. Cancer, 55: 580-585, 1993.[Medline]
  36. Gamallo C., Palacios J., Suarez A., Pizamo A., Navarro P., Quintanilla M., Cana A. Correlation of E-cadherin expression with differentiation grade and histological type in breast carcinoma. Am. J. Pathol., 142: 987-993, 1993.[Abstract]
  37. Umbas R., Schalken J. A., Alders T. W., Carter B. S., Karthas H. F. M., Schaafsma H. E., Debruyne F. M. J., Issacs W. B. Expression of the cellular adhesion molecule E-cadherin is reduced or absent in high-grade prostate cancer. Cancer Res., 52: 5104-5109, 1992.[Abstract/Free Full Text]
  38. Vleminckx K., Vakaet L., Jr., Mareel M., Fiers W., Van Roy F. Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell, 66: 107-119, 1991.[Medline]
  39. Frixen U. H., Behrens J., Sachs M., Eberle G., Voss B., Warda A., Loechner D., Birchmeier W. E-Cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol., 113: 173-185, 1991.[Abstract/Free Full Text]
  40. Collier I. E., Wilheim S. M., Eisen A. Z., Marmer B. L., Grant G. A., Selzter J. L., Kronberger A., He C., Bauer E. A., Goldberg G. I. H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloproteinase capable of degrading basement membrane collagen. J. Biol. Chem., 263: 6579-6587, 1988.[Abstract/Free Full Text]
  41. Welgus H. G., Campbell E. J., Cury J. D., Eisen A. Z., Senior R. M., Wilhelm S. M., Goldberg G. I. Neutral metalloproteinases produced by human mononuclear phagocytes: enzyme profile, regulation, and expression during cellular development. J. Clin. Investig., 86: 1496-1502, 1990.
  42. Campbell E. J., Cury J. D., Shapiro S. D., Goldberg G. I., Welgus H. G. Neutral proteinases of human mononuclear phagocytes. Cellular differentiation markedly alters cell phenotype for serine proteinases, metalloproteinases, and tissue inhibitor of metalloproteinases. J. Immunol., 146: 1286-1293, 1991.[Abstract]
  43. D’Errico A., Garbisa S., Liotta L. A., Castronovo V., Stetler-Stevenson W. G., Grigioni W. F. Augmentation of type IV collagenase, laminin receptor, and Ki67 proliferation antigen associated with human colon, gastric, and breast carcinoma progression. Mod. Pathol., 4: 239-246, 1991.[Medline]
  44. Liotta L. A. Tumor invasion and metastasis—role of the extracellular matrix: Rhoads Memorial Award Lecture. Cancer Res., 46: 1-7, 1986.[Free Full Text]
  45. Bucana C. D., Radinsky R., Dong Z., Sanchez R., Brigati D. J., Fidler I. J. A rapid colorimetric in situ mRNA hybridization technique using hyperbiotinylated oligonucleotide probes for analysis of mdr-1 in mouse colon carcinoma cells. J. Histochem. Cytochem., 41: 499-506, 1993.[Abstract]
  46. Radinsky R., Bucana C. D., Ellis L. M., Sanchez R., Cleary K. R., Brigati D. J., Fidler I. J. A rapid colorimetric in situ messenger RNA hybridization technique for analysis of epidermal growth factor receptor in paraffin-embedded surgical specimens of human colon carcinomas. Cancer Res., 53: 937-943, 1993.[Abstract/Free Full Text]
  47. Fleming I. D., Cooper J. S., Henson D. E., Hutter R. V. P., Kennedy B. J., Murphy G. P., O’Sullivan B., Sobin L. H., Yarbro J. W. . American Joint Committee on Cancer Cancer Staging Manual, 5th ed. 121-126, Lippincott-Raven Philadelphia 1997.
  48. Ullich A., Coussens L., Hayflick J. S., Dull T. J., Gray A., Tam A. W., Lee J., Yarden Y., Libermann T. A., Schlessinger J., Downward J., Mayes E. L. V., Whittle N., Waterfield M. D., Seeburg P. H. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature (Lond.), 309: 418-428, 1984.[Medline]
  49. Singh R. K., Bucana C. D., Gutman M., Fan D., Wilson M. R., Fidler I. J. Organ site-dependent expression of basic fibroblast growth factor in human renal cell carcinoma cells. Am. J. Pathol., 145: 365-374, 1994.[Abstract]
  50. Rogelj S., Weinberg R. A., Fanning P., Klagusbrun M. Basic fibroblast growth factor fused to a signal peptide transforms cells. Nature (Lond.), 331: 173-175, 1998.
  51. Leung D. W., Cachianes G., Kuang W. J., Goeddel D. V., Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (Washington DC), 246: 1306-1309, 1989.[Abstract/Free Full Text]
  52. Tischer E., Mitchell R., Hartman T., Silva M., Gospodarowicz D., Fiddes J. C., Abraham J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem., 266: 11947-11954, 1991.[Abstract/Free Full Text]
  53. Matsushima K., Morishita K., Yoshimura T., Lavu S., Kobayashi Y., Lew W., Appela E., Kung H. F., Leonard E. J., Oppenheim J. J. Molecular cloning of a human monocyte-derived neutrophil chemotactic factor (MDNCF) and the induction of MDNCF mRNA by interleukin-1 and tumor necrosis factor. J. Exp. Med., 167: 1883-1893, 1988.[Abstract/Free Full Text]
  54. Singh R. K., Gutman M., Radinsky R., Bucana C. D., Fidler I. J. Expression of interleukin-8 correlates with the metastatic potential of human melanoma cells in nude mice. Cancer Res., 54: 3242-3247, 1994.[Abstract/Free Full Text]
  55. Bussenmakers M. J. G., van Bokhoven A., Mees S. G. M., Kemler R., Schalken J. A. Molecular cloning and characterization of the human E-cadherin cDNA. Mol. Biol. Rep., 7: 123-128, 1993.
  56. Pearson W. R., Lipman D. J. Improved tools for biological sequence comparison. Proc. Natl. Acad. Sci. USA, 85: 2444-2448, 1988.[Abstract/Free Full Text]
  57. Park C-S., Manahan L. J., Brigati D. J. Automated molecular pathology: one hour in situ DNA hybridization. J. Histotechnol., 14: 219-229, 1991.
  58. Caruthers M. H., Beaucage S. L., Efcavitch J. W., Fisher E. F., Goldman R. A., DeHaseth P. L., Mandecki W., Matteucci M. D., Rosendahl M. S., Stabinsky Y. Chemical synthesis and biological studies on mutated gene-control regions. Cold Spring Harbor Symp. Quant. Biol., 47: 411-418, 1982.
  59. Reed J. A., Manahan L. J., Park C. S., Brigati D. J. Complete one-hour immunocytochemistry based on capillary action. Biotechniques, 13: 434-443, 1992.[Medline]
  60. Fisher L. D., van Belle G. . Biostatistics, 786-843, Wiley New York 1993.
  61. Kaplan E. L., Meier P. Nonparametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457-481, 1958.
  62. Crowley J., Breslow N. Remarks on the conservatism of (O-E)2/E in survival data. Biometrics, 31: 957-961, 1975.[Medline]
  63. Cox D. R. Regression models and life tables. J. Royal Stat. Soc. (B), 34: 187-220, 1972.
  64. Nagakawa T., Mori K., Nakano T., Kadoya M., Kobayashi H., Akiyama T., Kayahara M., Ohta T., Ueno K., Higashino Y., Konishi I., Miyazaki I. Perineural invasion of carcinoma of the pancreas and biliary tract. Br. J. Surg., 80: 619-621, 1993.[Medline]
  65. Nagakawa T., Nagamori M., Futakami F., Tsukioka Y., Kayahara Y., Ohta T., Ueno K., Miyazaki I. Results of extensive surgery for pancreatic carcinoma. Cancer (Phila.), 77: 640-645, 1996.[Medline]
  66. Kobari M., Sunamura M., Ohashi O., Saitoh Y., Yasa T., Matsuno S. Usefulness of Japanese staging in the prognosis of patients treated operatively for adenocarcinoma of the head of the pancreas. J. Am. Coll. Surg., 182: 24-32, 1996.[Medline]
  67. Sperti C., Pasquarli C., Piccoli A., Pedrazzoli S. Survival after resection for ductal adenocarcinoma of the pancreas. Br. J. Surg., 83: 625-631, 1996.[Medline]
  68. Fidler I. J. Critical factors in the biology of human cancer metastasis: Twenty-eighth GHA Clowes Memorial Award Lecture. Cancer Res., 50: 6130-6138, 1990.[Abstract/Free Full Text]
  69. Fidler I. J. Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125I-5-iodo-2'-deoxyuridine. J. Natl. Cancer Inst., 45: 773-782, 1970.
  70. Fidler I. J., Kripke M. L. Metastasis results from preexisting variant cells within a malignant tumor. Science (Washington DC), 197: 893-895, 1977.[Abstract/Free Full Text]
  71. Takeichi M. Cadherins: a molecular family important in selective cell-cell adhesion. Annu. Rev. Biochem., 59: 237-252, 1990.[Medline]
  72. Shimoyama Y., Hirohashi S., Hirano S., Noguchi M., Shimasato Y., Takeichi M., Abe O. Cadherin cell adhesion molecules in human epithelial tissues and carcinomas. Cancer Res., 49: 2128-2133, 1989.[Abstract/Free Full Text]
  73. Oka H., Shiozaki H., Kobayashi H., Inoue M., Tahara H., Kobayashi T., Takatsuka Y., Matsuyoshi N., Hirano S., Takeichi M., Mori T. Expression of E-cadherin cell adhesion molecule in human breast cancer tissues and its relationship to metastasis. Cancer Res., 53: 1696-1701, 1993.[Abstract/Free Full Text]
  74. Schipper J. H., Frixen U. H., Behrens J., Unger A., Jahnke K., Birchmeier W. E-Cadherin expression in squamous carcinomas of the head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res., 51: 6328-6337, 1991.[Medline]
  75. Shimoyama Y., Hirohashi S. Expression of E- and P-cadherin in gastric carcinomas. Cancer Res., 51: 2185-2192, 1991.[Abstract/Free Full Text]
  76. Liotta L. A., Stetler-Stevenson W. G. Metalloproteinases and cancer invasion. Semin. Cancer Biol., 1: 99-106, 1990.[Medline]
  77. Matrisian L. M., Bowden G. T. Stromelysin/transin and tumor progression. Semin. Cancer Biol., 1: 107-115, 1990.[Medline]
  78. Murphy G., Docherty A. J. P. The matrix metalloproteinases and their inhibitors. Am. J. Respir. Cell Mol. Biol., 7: 120-125, 1992.
  79. Stetler-Stevenson W. G. Type IV collagenase in tumor invasion and metastases. Cancer Metastasis Rev., 9: 289-303, 1990.[Medline]
  80. Albini A., Melchiori A., Santi L., Liotta L. A., Brown P. D., Stetler-Stevenson W. G. Tumor cell invasion by TIMP-2. J. Natl. Cancer Inst., 83: 775-779, 1991.[Abstract/Free Full Text]
  81. DeClerck Y. A., Yean T-D., Chan D., Shimada H., Landley K. E. Inhibition of tumor invasion of smooth muscle cell layer by recombinant human metalloproteinase inhibitor. Cancer Res., 51: 2151-2157, 1991.[Abstract/Free Full Text]
  82. Conlon K. C., Klimstra D. S., Brennan M. F. Long-term survival after curative resection for pancreatic ductal adenocarcinoma. Clinicopathologic analysis of 5-year survivors. Ann. Surg., 223: 273-279, 1996.[Medline]
  83. Seki H., Tanaka J., Sato Y., Kato Y., Umezawa A., Koyama K. Neural cell adhesion molecule (NCAM) and perineural invasion in bile duct cancer. J. Surg. Oncol., 53: 78-83, 1993.[Medline]



This article has been cited by other articles:


Home page
 Cancer Res.Home page
T. Nakamura, T. Kuwai, Y. Kitadai, T. Sasaki, D. Fan, K. R. Coombes, S.-J. Kim, and I. J. Fidler
Zonal Heterogeneity for Gene Expression in Human Pancreatic Carcinoma
Cancer Res., August 15, 2007; 67(16): 7597 - 7604.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
E. Buck, A. Eyzaguirre, S. Barr, S. Thompson, R. Sennello, D. Young, K. K. Iwata, N. W. Gibson, P. Cagnoni, and J. D. Haley
Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition
Mol. Cancer Ther., February 1, 2007; 6(2): 532 - 541.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, E. Galardi, M. Duquette, J. Lawler, and S. Parangi
Antiangiogenic Treatment with Three Thrombospondin-1 Type 1 Repeats versus Gemcitabine in an Orthotopic Human Pancreatic Cancer Model
Clin. Cancer Res., August 1, 2005; 11(15): 5622 - 5630.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
X. Zhang, E. Galardi, M. Duquette, M. Delic, J. Lawler, and S. Parangi
Antiangiogenic Treatment with the Three Thrombospondin-1 Type 1 Repeats Recombinant Protein in an Orthotopic Human Pancreatic Cancer Model
Clin. Cancer Res., March 15, 2005; 11(6): 2337 - 2344.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
J. Sanceau, S. Truchet, and B. Bauvois
Matrix Metalloproteinase-9 Silencing by RNA Interference Triggers the Migratory-adhesive Switch in Ewing's Sarcoma Cells
J. Biol. Chem., September 19, 2003; 278(38): 36537 - 36546.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
B. Nawrocki-Raby, C. Gilles, M. Polette, C. Martinella-Catusse, N. Bonnet, E. Puchelle, J.-M. Foidart, F. van Roy, and P. Birembaut
E-Cadherin Mediates MMP Down-Regulation in Highly Invasive Bronchial Tumor Cells
Am. J. Pathol., August 1, 2003; 163(2): 653 - 661.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. Kuniyasu, R. Ukai, D. Johnston, P. Troncoso, I. J. Fidler, and C. A. Pettaway
The Relative mRNA Expression Levels of Matrix Metalloproteinase to E-Cadherin in Prostate Biopsy Specimens Distinguishes Organ-confined from Advanced Prostate Cancer at Radical Prostatectomy
Clin. Cancer Res., June 1, 2003; 9(6): 2185 - 2194.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
A. M. Lowy, C. Fenoglio-Preiser, O. J. Kim, J. Kordich, A. Gomez, J. Knight, L. James, and J. Groden
Dysregulation of {beta}-Catenin Expression Correlates With Tumor Differentiation in Pancreatic Duct Adenocarcinoma
Ann. Surg. Oncol., April 1, 2003; 10(3): 284 - 290.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. Kedar, C. H. Baker, J. J. Killion, C. P. N. Dinney, and I. J. Fidler
Blockade of the Epidermal Growth Factor Receptor Signaling Inhibits Angiogenesis Leading to Regression of Human Renal Cell Carcinoma Growing Orthotopically in Nude Mice
Clin. Cancer Res., November 1, 2002; 8(11): 3592 - 3600.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. F. Huang, S.-J. Kim, A. T. Lee, T. Karashima, C. Bucana, D. Kedar, P. Sweeney, B. Mian, D. Fan, D. Shepherd, et al.
Inhibition of Growth and Metastasis of Orthotopic Human Prostate Cancer in Athymic Mice by Combination Therapy with Pegylated Interferon-{alpha}-2b and Docetaxel
Cancer Res., October 15, 2002; 62(20): 5720 - 5726.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. Bloomston, E. E. Zervos, and A. S. Rosemurgy II
Matrix Metalloproteinases and Their Role in Pancreatic Cancer: A Review of Preclinical Studies and Clinical Trials
Ann. Surg. Oncol., August 1, 2002; 9(7): 668 - 674.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Nakata, Y. Qing Wang, M. Yashiro, N. Nishioka, H. Tanaka, M. Ohira, T. Ishikawa, H. Nishino, and K. Hirakawa
Prognostic Value of Microsatellite Instability in Resectable Pancreatic Cancer
Clin. Cancer Res., August 1, 2002; 8(8): 2536 - 2540.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Tedjarati, C. H. Baker, S. Apte, S. Huang, J. K. Wolf, J. J. Killion, and I. J. Fidler
Synergistic Therapy of Human Ovarian Carcinoma Implanted Orthotopically in Nude Mice by Optimal Biological Dose of Pegylated Interferon {alpha} Combined with Paclitaxel
Clin. Cancer Res., July 1, 2002; 8(7): 2413 - 2422.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. Inoue, M. Kamada, J. W. Slaton, S. Fukata, C. Yoshikawa, P. Tamboli, C. P. N. Dinney, and T. Shuin
The Prognostic Value of Angiogenesis and Metastasis-related Genes for Progression of Transitional Cell Carcinoma of the Renal Pelvis and Ureter
Clin. Cancer Res., June 1, 2002; 8(6): 1863 - 1870.
[Abstract] [Full Text] [PDF]

Home page